Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04897217
Other study ID # IRB00074615
Secondary ID WFBCCC 99321P30C
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date June 30, 2023
Est. completion date November 2026

Study information

Verified date July 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive megestrol acetate to treat their hyperplasia. While both methods are commonly used in practice, investigators would like to see what effects each treatment has on uterine tissue.


Description:

Primary Objective: To determine if Levonorgestrel-releasing intrauterine system is of equal efficacy to the standard systemic progestin therapy (megestrol acetate) based on endometrial sampling at 6 months after randomization. Non-inferiority analysis. Secondary Objective(s): - To determine the safety of each treatment modality. - Determine the feasibility of transvaginal ultrasound to predict treatment response.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 2026
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Complex atypical endometrial hyperplasia only. Confirmed by pathology report. - Normal renal function and liver function tests. - Age 18 or older. - The effects of megestrol acetate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because megestrol acetate is known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. Exclusion Criteria: - Prior complex atypical endometrial hyperplasia or carcinoma. - Prior hormone sensitive malignancy.] - Exogenous estrogen or progestin use presently or within the past 12 months. - Standard contraindications to progestin therapy. - Standard contraindications to intrauterine device use. - Simple hyperplasia, complex hyperplasia without atypia (may be present in addition to atypical endometrial hyperplasia). - Endometrial carcinoma (worrisome or possible carcinoma not exclusionary but requires dilatation and curettage if based only on office biopsy). - Pregnant women are excluded from this study because megestrol acetate has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with megestrol acetate, breastfeeding should be discontinued if the mother is treated with megestrol acetate.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Megestrol Acetate
The control arm will consist of oral progesterone therapy (megestrol acetate 160mg po daily). The intervention will be administered on an outpatient basis.
Levonorgestrel Drug Implant
Participants in the comparison arm will have a levonorgestrel intrauterine device placed in the office or in the operating room if the office procedure not tolerated or if they have not had a prior dilation and curettage.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Histologic Response Scoring of Biopsy Specimens The primary outcome is a response score (0: no response, 1: incomplete response, 2: complete response): Score -1 will be assigned to specimens with progression of disease (ie. Endometrial carcinoma); Score 0 will be assigned to specimens with atypical hyperplasia; Score 1 will be assigned to specimens with benign hyperplasia and will be indicative partial response to therapy; Score 2 will be assigned to specimens without hyperplasia and will be indicative of complete response to therapy. All study cases will be reviewed by a pathologist and all cases will be scored following the standard 2014 WHO classification of endometrial hyperplasia. Investigators will compare the estimated 90% confidence interval (CI) of the levonorgestrel-releasing Intrauterine system versus the standard therapy from the noninferiority trial to a predefined margin. 6 months
Secondary Number of Toxicities for Each Treatment Toxicities for each treatment modality based on standard toxicity scoring using NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Investigators will compare the number of toxicities between the two treatment groups using chi-squared tests. Up to 8 months
Secondary Pathological Response to Treatment The pathological response variable will be treated as a binary variable, the Wilcoxon rank sum test will be used to explore the association between measurement of the endometrial stripe and the response outcome at each visit. Score -1 will be assigned to specimens with progression of disease (ie. Endometrial carcinoma); Score 0 will be assigned to specimens with atypical hyperplasia; Score 1 will be assigned to specimens with benign hyperplasia and will be indicative partial response to therapy; Score 2 will be assigned to specimens without hyperplasia and will be indicative of complete response to therapy. Up to 8 months
See also
  Status Clinical Trial Phase
Completed NCT05378152 - Assessing the Benefit of Pipelle Biopsy in Patients With Postmenopausal Bleeding and an Atrophic-appearing Cavity N/A
Withdrawn NCT00123175 - Treatment of Endometrial Hyperplasia With an Intrauterine Device (IUD) Phase 1/Phase 2
Completed NCT02100137 - Women With Asymptomatic Endometrial Hyperplasia N/A
Completed NCT00242710 - Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women Phase 3
Not yet recruiting NCT04191603 - TWO DÄ°FFERENT ELECTROSURGERY DEVICES AS MONOPOLAR HOOC AND PLASMAKINETIC BIPOLAR SPATULA EFFECTIVENESS DURING COLPOTOMY N/A
Completed NCT03032848 - Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Phase 4
Completed NCT00339651 - Preliminary Study of Endometrial Hyperplasia Groundwork for a Study to Define Precursors of Endometrial Cancer
Recruiting NCT01234818 - Management of Endometrial Hyperplasia With a LNG-IUS: Multicenter Study: KGOG2006 Phase 2
Recruiting NCT04362046 - Fertility Sparing Management of EndomeTrial Cancer and Hyperplasia N/A
Active, not recruiting NCT05257057 - Frequency of Endometrial Cancer Precursors Associated With Lynch Syndrome
Completed NCT01499602 - Efficacy of LNG-IUS for Treatment of Non-atypical Endometrial Hyperplasia in Perimenopausal Women N/A
Completed NCT00883662 - Mirena Observational Program N/A
Completed NCT01074892 - A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Phase 4
Not yet recruiting NCT05903131 - A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia Phase 2
Not yet recruiting NCT05829460 - Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia Phase 2
Recruiting NCT03176992 - Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding Phase 2
Not yet recruiting NCT00919919 - Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Phase 2
Recruiting NCT03207126 - Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy? N/A
Recruiting NCT03207061 - Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer? N/A
Completed NCT03207074 - Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue? N/A